Difference between revisions of "CLL Tables: Regions of Recurrent Copy Number Change and CN-LOH"
[unchecked revision] | [unchecked revision] |
(Adding references and gene links) |
|||
Line 286: | Line 286: | ||
Abbreviations: CNA = copy number aberration; CLL = chronic lymphocytic leukemia; CN-LOH = copy-neutral loss-of-heterozygosity | Abbreviations: CNA = copy number aberration; CLL = chronic lymphocytic leukemia; CN-LOH = copy-neutral loss-of-heterozygosity | ||
+ | |||
+ | |||
+ | '''Table 2. Recurring regions of CN-LOH in CLL''' | ||
+ | {| class="wikitable" | ||
+ | |'''CN-LOH''' | ||
+ | |'''Candidate Gene''' | ||
+ | |'''Association''' | ||
+ | |'''Strength of Evidence for Prognosis (Level*)''' | ||
+ | |'''References''' | ||
+ | |- | ||
+ | |13q | ||
+ | |''miR15a/16-1'' | ||
+ | |Biallelic deletion of 13q | ||
+ | |Established (1) | ||
+ | |<ref name=":13">{{Cite journal|last=Hagenkord|first=Jill M.|last2=Monzon|first2=Federico A.|last3=Kash|first3=Shera F.|last4=Lilleberg|first4=Stan|last5=Xie|first5=Qingmei|last6=Kant|first6=Jeffrey A.|date=2010-03|title=Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays|url=https://pubmed.ncbi.nlm.nih.gov/20075210|journal=The Journal of molecular diagnostics: JMD|volume=12|issue=2|pages=184–196|doi=10.2353/jmoldx.2010.090118|issn=1943-7811|pmc=2871725|pmid=20075210}}</ref><ref>{{Cite journal|last=Pfeifer|first=Dietmar|last2=Pantic|first2=Milena|last3=Skatulla|first3=Ilona|last4=Rawluk|first4=Justyna|last5=Kreutz|first5=Clemens|last6=Martens|first6=Uwe M.|last7=Fisch|first7=Paul|last8=Timmer|first8=Jens|last9=Veelken|first9=Hendrik|date=2007-02-01|title=Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays|url=https://pubmed.ncbi.nlm.nih.gov/17053054|journal=Blood|volume=109|issue=3|pages=1202–1210|doi=10.1182/blood-2006-07-034256|issn=0006-4971|pmid=17053054}}</ref><ref name=":14">{{Cite journal|last=Edelmann|first=Jennifer|last2=Holzmann|first2=Karlheinz|last3=Miller|first3=Florian|last4=Winkler|first4=Dirk|last5=Bühler|first5=Andreas|last6=Zenz|first6=Thorsten|last7=Bullinger|first7=Lars|last8=Kühn|first8=Michael W. M.|last9=Gerhardinger|first9=Andreas|date=2012-12-06|title=High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations|url=https://pubmed.ncbi.nlm.nih.gov/23047824|journal=Blood|volume=120|issue=24|pages=4783–4794|doi=10.1182/blood-2012-04-423517|issn=1528-0020|pmid=23047824}}</ref><ref>{{Cite journal|last=Grygalewicz|first=Beata|last2=Woroniecka|first2=Renata|last3=Rygier|first3=Jolanta|last4=Borkowska|first4=Klaudia|last5=Rzepecka|first5=Iwona|last6=Łukasik|first6=Martyna|last7=Budziłowska|first7=Agnieszka|last8=Rymkiewicz|first8=Grzegorz|last9=Błachnio|first9=Katarzyna|date=2016|title=Monoallelic and biallelic deletions of 13q14 in a group of CLL/SLL patients investigated by CGH Haematological Cancer and SNP array (8x60K)|url=https://pubmed.ncbi.nlm.nih.gov/26740820|journal=Molecular Cytogenetics|volume=9|pages=1|doi=10.1186/s13039-015-0212-x|issn=1755-8166|pmc=4702365|pmid=26740820}}</ref><ref>{{Cite journal|last=Gunnarsson|first=Rebeqa|last2=Mansouri|first2=Larry|last3=Isaksson|first3=Anders|last4=Göransson|first4=Hanna|last5=Cahill|first5=Nicola|last6=Jansson|first6=Mattias|last7=Rasmussen|first7=Markus|last8=Lundin|first8=Jeanette|last9=Norin|first9=Stefan|date=2011-08|title=Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/21546498|journal=Haematologica|volume=96|issue=8|pages=1161–1169|doi=10.3324/haematol.2010.039768|issn=1592-8721|pmc=3148910|pmid=21546498}}</ref><ref name=":15">{{Cite journal|last=Parker|first=H.|last2=Rose-Zerilli|first2=M. J. J.|last3=Parker|first3=A.|last4=Chaplin|first4=T.|last5=Wade|first5=R.|last6=Gardiner|first6=A.|last7=Griffiths|first7=M.|last8=Collins|first8=A.|last9=Young|first9=B. D.|date=2011-03|title=13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/21151023|journal=Leukemia|volume=25|issue=3|pages=489–497|doi=10.1038/leu.2010.288|issn=1476-5551|pmid=21151023}}</ref><ref>{{Cite journal|last=Lehmann|first=Sören|last2=Ogawa|first2=Seishi|last3=Raynaud|first3=Sophie D.|last4=Sanada|first4=Masashi|last5=Nannya|first5=Yasuhito|last6=Ticchioni|first6=Michel|last7=Bastard|first7=Christian|last8=Kawamata|first8=Norihiko|last9=Koeffler|first9=H. Phillip|date=2008-03-15|title=Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/18246537|journal=Cancer|volume=112|issue=6|pages=1296–1305|doi=10.1002/cncr.23270|issn=0008-543X|pmid=18246537}}</ref><ref>{{Cite journal|last=Ouillette|first=Peter|last2=Collins|first2=Roxane|last3=Shakhan|first3=Sajid|last4=Li|first4=Jinghui|last5=Li|first5=Cheng|last6=Shedden|first6=Kerby|last7=Malek|first7=Sami N.|date=2011-11-01|title=The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/21890456|journal=Clinical Cancer Research: An Official Journal of the American Association for Cancer Research|volume=17|issue=21|pages=6778–6790|doi=10.1158/1078-0432.CCR-11-0785|issn=1078-0432|pmc=3207001|pmid=21890456}}</ref> | ||
+ | |- | ||
+ | |17p13 | ||
+ | |''[[TP53]]'' | ||
+ | |Homozygous ''TP53'' mutations | ||
+ | |Established (1) | ||
+ | |<ref name=":13" /><ref name=":14" /><ref name=":16">{{Cite journal|last=Stevens-Kroef|first=Marian Jpl|last2=van den Berg|first2=Eva|last3=Olde Weghuis|first3=Daniel|last4=Geurts van Kessel|first4=Ad|last5=Pfundt|first5=Rolph|last6=Linssen-Wiersma|first6=Matty|last7=Benjamins|first7=Marloes|last8=Dijkhuizen|first8=Trijnie|last9=Groenen|first9=Patricia Jta|date=2014-01-09|title=Identification of prognostic relevant chromosomal abnormalities in chronic lymphocytic leukemia using microarray-based genomic profiling|url=https://pubmed.ncbi.nlm.nih.gov/24401281|journal=Molecular Cytogenetics|volume=7|issue=1|pages=3|doi=10.1186/1755-8166-7-3|issn=1755-8166|pmc=3905918|pmid=24401281}}</ref><ref name=":15" /><ref>{{Cite journal|last=Saddler|first=Chris|last2=Ouillette|first2=Peter|last3=Kujawski|first3=Lisa|last4=Shangary|first4=Sanjeev|last5=Talpaz|first5=Moshe|last6=Kaminski|first6=Mark|last7=Erba|first7=Harry|last8=Shedden|first8=Kerby|last9=Wang|first9=Shaomeng|date=2008-02-01|title=Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/17971485|journal=Blood|volume=111|issue=3|pages=1584–1593|doi=10.1182/blood-2007-09-112698|issn=0006-4971|pmid=17971485}}</ref> | ||
+ | |- | ||
+ | |11q13-qter | ||
+ | |Includes ''[[ATM]]'' | ||
+ | |Monoallelic ''ATM'' deletion | ||
+ | |Suspected (2) | ||
+ | |<ref name=":14" /><ref name=":15" /> | ||
+ | |- | ||
+ | |20q11 | ||
+ | |Unknown | ||
+ | |None | ||
+ | |N/A (3) | ||
+ | |<ref name=":16" /><ref>{{Cite journal|last=Pei|first=Jianming|last2=Robu|first2=Valentin|last3=Feder|first3=Madelyn|last4=Cheung|first4=Mitchell|last5=Neumann-Domer|first5=Erin|last6=Talarchek|first6=Jacqueline|last7=Dulaimi|first7=Essel|last8=Millenson|first8=Michael M.|last9=Testa|first9=Joseph R.|date=2014-03|title=Copy neutral loss of heterozygosity in 20q in chronic lymphocytic leukemia/small lymphocytic lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/24704113|journal=Cancer Genetics|volume=207|issue=3|pages=98–102|doi=10.1016/j.cancergen.2014.02.005|issn=2210-7762|pmc=4010307|pmid=24704113}}</ref> | ||
+ | |- | ||
+ | |1p36 | ||
+ | |Unknown | ||
+ | |None | ||
+ | |N/A (3) | ||
+ | |<ref name=":14" /><ref>{{Cite journal|last=Xu|first=Xinjie|last2=Johnson|first2=Eric B.|last3=Leverton|first3=Lisa|last4=Arthur|first4=Ashley|last5=Watson|first5=Quinn|last6=Chang|first6=Faye L.|last7=Raca|first7=Gordana|last8=Laffin|first8=Jennifer J.|date=2013-09|title=The advantage of using SNP array in clinical testing for hematological malignancies--a comparative study of three genetic testing methods|url=https://pubmed.ncbi.nlm.nih.gov/24269304|journal=Cancer Genetics|volume=206|issue=9-10|pages=317–326|doi=10.1016/j.cancergen.2013.09.001|issn=2210-7762|pmid=24269304}}</ref> | ||
+ | |} | ||
+ | <nowiki>*</nowiki>Level 1: present in WHO classification or professional practice guidelines; Level 2: recurrent in well-powered studies with suspected clinical significance; Level 3: recurrent, but uncertain prognostic significance | ||
==Reference== | ==Reference== | ||
<references /> | <references /> |
Revision as of 21:27, 7 November 2020
Table 1 - Regions of Recurrent Copy Number Change in CLL (Literature Review). The is a list of clinically significant and/or recurrent CNAs selected and evaluated based on a systematic literature search performed on 72 peer-reviewed manuscripts focusing on CNAs and CN-LOH assessment in CLL published between 2000 and 2017. Table derived from Chun et al., 2018 [PMID 30554732] with permission from Cancer Genetics.
Chromosome/
Region |
Abnormality Type | Prevalence (%) | Relevant Genes | Strength of Evidence for Gene | Prognostic Significance | Strength of Evidence for Prognosis (Level*) | Comments | References |
1p | Gain | ?2-5 | Unknown | N/A | Favorable | Suspected (2) | [1] [2] [3] | |
1q23.2q23.3 | Loss | 15 | Unknown | N/A | Unknown | N/A (3) | [4] [5] [6] | |
2p12p25.3 | Gain | 5-30 | ACP1, MYCN, ALK, REL, BCL11A | MYCN (Established), REL, BCL11A (Candidate) | Unfavorable | Established (if MYCN included) (1) | [1] [2] [3] [4] [5] [7] [8] [9] [10] [11] [12] [13] | |
3p21.31 | Loss | 1-5 | ATRIP, CDC25A | Candidate | Unknown | N/A (3) | [4] [14] [15] | |
3q | Gain | 2-19 | Unknown | N/A | Unfavorable | Suspected (2) | Appears to be particularly prevalent in Japanese | [2] [16] [17] |
4p15.2p16.3 | Loss | 14 | Unknown | N/A | Unfavorable (occurred with del(11q) or del(17p)) | Suspected (2) | [18] | |
6p25.3 | Gain | 1 | Unknown | N/A | Unknown | N/A (3) | [4] | |
6p22.1 | Loss | 1 | Histone cluster, HFE | Candidate | Unknown | N/A (3) | [4] | |
6q | Loss | 3-6 | FOXO3 | Candidate | Intermediate | Suspected (2) | [19] [20] [21] [22] | |
7p | Gain | 5-6 | Unknown | N/A | Intermediate | Suspected (2) | [2] | |
7q | Loss | 1-2 | Unknown | N/A | Unknown | N/A (3) | [2] [10] | |
8p21 | Loss | 2-5 | TRIM35 | Candidate | Unfavorable | Suspected (2) | Associated with established unfavorable changes (11q- and 17p-). Not established as an independent prognosticator | [2] [23] |
8q24.1 | Gain | 5 | MYC | Candidate | Unfavorable | Suspected (2) | Often associated with 11q and 17p deletion; may not be independent [2] | [2] [4] |
9q13q21.11 | Loss | 1 | Unknown | N/A | Unknown | N/A (3) | [4] | |
10q24 | Loss | 2 | Unknown | N/A | Unknown | N/A (3) | Clustered around NFKB2 gene locus | [4] [9] [24] |
11q22.3 | Loss | 10-20 | ATM, BIRC3, MRE11, H2AFX | ATM established, Others Candidate | Unfavorable | Established (1) | [25] | |
12 | Gain | 10-20 | Unknown | N/A | Intermediate | Established (1) | Unfavorable if NOTCH1 mutation is present | [25] |
13q14 | Loss | 50-60 | DLEU2, MIR15A, MIR16-1, DLEU1 | Established | Favorable | Established (1) | Co-deletion of RB1 may negatively impact time to treatment | [25] [26] [27] |
14q24.1q32.3 | Loss | 2 | Unknown | N/A | Unknown | N/A (3) | Associated with trisomy 12 | [4] [28] [29] |
15q15.1 | Loss | 4 | MGA | Candidate | Unknown | N/A (3) | [4] [9] | |
17p13.1 | Loss | 5-15 | TP53 | Established | Unfavorable | Established (1) | [25] | |
17q | Gain | 1 | Unknown | N/A | Unfavorable | Suspected (2) | [2] | |
18p | Loss | 3 | Unknown | N/A | Unfavorable | Suspected (2) | [2] [4] | |
18 | Gain | 4 | Unknown | N/A | Unfavorable | Established (1) | Associated with trisomy 12 | [30] |
19 | Gain | 2-5 | Unknown | N/A | Unfavorable | Established (1) | Associated with trisomy 12 | [4] [9] [18] [24] [30] |
Genomic complexity | 3 or more CNAs | 10-15 | N/A | Unfavorable | Established (1) | [9] [10] [14] [31] | ||
Chromothripsis | (>10 copy number states of 2 and 3) | 5 | SETD2, other markers across genome not defined | Established | Unfavorable | Established (1) | [4] [27] [32] |
*Level 1: present in WHO classification or professional practice guidelines; Level 2: recurrent in well-powered studies with suspected clinical significance; Level 3: recurrent, but uncertain prognostic significance.
Abbreviations: CNA = copy number aberration; CLL = chronic lymphocytic leukemia; CN-LOH = copy-neutral loss-of-heterozygosity
Table 2. Recurring regions of CN-LOH in CLL
CN-LOH | Candidate Gene | Association | Strength of Evidence for Prognosis (Level*) | References |
13q | miR15a/16-1 | Biallelic deletion of 13q | Established (1) | [33][34][35][36][37][38][39][40] |
17p13 | TP53 | Homozygous TP53 mutations | Established (1) | [33][35][41][38][42] |
11q13-qter | Includes ATM | Monoallelic ATM deletion | Suspected (2) | [35][38] |
20q11 | Unknown | None | N/A (3) | [41][43] |
1p36 | Unknown | None | N/A (3) | [35][44] |
*Level 1: present in WHO classification or professional practice guidelines; Level 2: recurrent in well-powered studies with suspected clinical significance; Level 3: recurrent, but uncertain prognostic significance
Reference
- ↑ 1.0 1.1 D, Pfeifer; et al. (2007). "Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays". PMID 17053054.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 J, Houldsworth; et al. (2014). "Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia". doi:10.3109/10428194.2013.845882. PMC 6905429. PMID 24047479.CS1 maint: PMC format (link)
- ↑ 3.0 3.1 E, Chapiro; et al. (2010). "Gain of the short arm of chromosome 2 (2p) is a frequent recurring chromosome aberration in untreated chronic lymphocytic leukemia (CLL) at advanced stages". PMID 19406473.
- ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 J, Edelmann; et al. (2012). "High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations". PMID 23047824.
- ↑ 5.0 5.1 D, Ma; et al. (2011). "Array comparative genomic hybridization analysis identifies recurrent gain of chromosome 2p25.3 involving the ACP1 and MYCN genes in chronic lymphocytic leukemia". doi:10.1016/j.clml.2011.03.031. PMC 4845643. PMID 22035742.CS1 maint: PMC format (link)
- ↑ A, Tyybakinoja; et al. (2007). "High-resolution oligonucleotide array-CGH pinpoints genes involved in cryptic losses in chronic lymphocytic leukemia". PMID 17901694.
- ↑ L, Shao; et al. (2010). "Array comparative genomic hybridization detects chromosomal abnormalities in hematological cancers that are not detected by conventional cytogenetics". doi:10.2353/jmoldx.2010.090192. PMC 2928432. PMID 20724749.CS1 maint: PMC format (link)
- ↑ A, Patel; et al. (2008). "Validation of a targeted DNA microarray for the clinical evaluation of recurrent abnormalities in chronic lymphocytic leukemia". PMID 18161787.
- ↑ 9.0 9.1 9.2 9.3 9.4 Mj, Stevens-Kroef; et al. (2014). "Identification of prognostic relevant chromosomal abnormalities in chronic lymphocytic leukemia using microarray-based genomic profiling". doi:10.1186/1755-8166-7-3. PMC 3905918. PMID 24401281.CS1 maint: PMC format (link)
- ↑ 10.0 10.1 10.2 Cd, Schweighofer; et al. (2013). "Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes". doi:10.1016/j.jmoldx.2012.09.006. PMC 3586684. PMID 23273604.CS1 maint: PMC format (link)
- ↑ S, Fabris; et al. (2013). "Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia". PMID 23044996.
- ↑ F, Forconi; et al. (2008). "Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion". PMID 18752589.
- ↑ M, Jarosova; et al. (2010). "Gain of chromosome 2p in chronic lymphocytic leukemia: significant heterogeneity and a new recurrent dicentric rearrangement". PMID 20078324.
- ↑ 14.0 14.1 Ka, Kolquist; et al. (2011). "Evaluation of chronic lymphocytic leukemia by oligonucleotide-based microarray analysis uncovers novel aberrations not detected by FISH or cytogenetic analysis". doi:10.1186/1755-8166-4-25. PMC 3253687. PMID 22087757.CS1 maint: PMC format (link)
- ↑ I, Salaverria; et al. (2015). "Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia". doi:10.1002/gcc.22277. PMC 4832286. PMID 26305789.CS1 maint: PMC format (link)
- ↑ N, Kawamata; et al. (2013). "Genetic differences between Asian and Caucasian chronic lymphocytic leukemia". doi:10.3892/ijo.2013.1966. PMC 3775563. PMID 23708256.CS1 maint: PMC format (link)
- ↑ K, Tsukasaki; et al. (2006). "Comparative genomic hybridization analysis of Japanese B-cell chronic lymphocytic leukemia: correlation with clinical course". PMID 16321855.
- ↑ 18.0 18.1 R, Gunnarsson; et al. (2011). "Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia". doi:10.3324/haematol.2010.039768. PMC 3148910. PMID 21546498.CS1 maint: PMC format (link)
- ↑ A, Cuneo; et al. (2004). "Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis". PMID 14712287.
- ↑ Dm, Wang; et al. (2011). "Intermediate prognosis of 6q deletion in chronic lymphocytic leukemia". PMID 21281237.
- ↑ M, Jarosova; et al. (2017). "Chromosome 6q deletion correlates with poor prognosis and low relative expression of FOXO3 in chronic lymphocytic leukemia patients". PMID 28699185.
- ↑ C, Nabhan; et al. (2015). "Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era". PMID 26181643.
- ↑ V, Grubor; et al. (2009). "Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA)". PMID 18922857.
- ↑ 24.0 24.1 C, Schwaenen; et al. (2004). "Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations". doi:10.1073/pnas.0304717101. PMC 327147. PMID 14730057.CS1 maint: PMC format (link)
- ↑ 25.0 25.1 25.2 25.3 Wg, Wierda; et al. (2017). "NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017". PMID 28275031.
- ↑ M, Dal Bo; et al. (2011). "13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia". PMID 21563234.
- ↑ 27.0 27.1 Sn, Malek (2013). "The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia". doi:10.1038/onc.2012.411. PMC 3676480. PMID 23001040.CS1 maint: PMC format (link)
- ↑ Pt, Greipp; et al. (2013). "Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis". doi:10.1111/bjh.12534. PMC 3907074. PMID 24032430.CS1 maint: PMC format (link)
- ↑ A, Cosson; et al. (2014). "14q deletions are associated with trisomy 12, NOTCH1 mutations and unmutated IGHV genes in chronic lymphocytic leukemia and small lymphocytic lymphoma". PMID 24729385.
- ↑ 30.0 30.1 R, Ibbotson; et al. (2012). "Coexistence of trisomies of chromosomes 12 and 19 in chronic lymphocytic leukemia occurs exclusively in the rare IgG-positive variant". PMID 21788947.
- ↑ Sr, Gunn; et al. (2008). "The HemeScan test for genomic prognostic marker assessment in chronic lymphocytic leukemia". PMID 23495782.
- ↑ H, Parker; et al. (2016). "Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia". doi:10.1038/leu.2016.134. PMC 5023049. PMID 27282254.CS1 maint: PMC format (link)
- ↑ 33.0 33.1 Hagenkord, Jill M.; et al. (2010-03). "Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays". The Journal of molecular diagnostics: JMD. 12 (2): 184–196. doi:10.2353/jmoldx.2010.090118. ISSN 1943-7811. PMC 2871725. PMID 20075210. Check date values in:
|date=
(help) - ↑ Pfeifer, Dietmar; et al. (2007-02-01). "Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays". Blood. 109 (3): 1202–1210. doi:10.1182/blood-2006-07-034256. ISSN 0006-4971. PMID 17053054.
- ↑ 35.0 35.1 35.2 35.3 Edelmann, Jennifer; et al. (2012-12-06). "High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations". Blood. 120 (24): 4783–4794. doi:10.1182/blood-2012-04-423517. ISSN 1528-0020. PMID 23047824.
- ↑ Grygalewicz, Beata; et al. (2016). "Monoallelic and biallelic deletions of 13q14 in a group of CLL/SLL patients investigated by CGH Haematological Cancer and SNP array (8x60K)". Molecular Cytogenetics. 9: 1. doi:10.1186/s13039-015-0212-x. ISSN 1755-8166. PMC 4702365. PMID 26740820.
- ↑ Gunnarsson, Rebeqa; et al. (2011-08). "Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia". Haematologica. 96 (8): 1161–1169. doi:10.3324/haematol.2010.039768. ISSN 1592-8721. PMC 3148910. PMID 21546498. Check date values in:
|date=
(help) - ↑ 38.0 38.1 38.2 Parker, H.; et al. (2011-03). "13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia". Leukemia. 25 (3): 489–497. doi:10.1038/leu.2010.288. ISSN 1476-5551. PMID 21151023. Check date values in:
|date=
(help) - ↑ Lehmann, Sören; et al. (2008-03-15). "Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia". Cancer. 112 (6): 1296–1305. doi:10.1002/cncr.23270. ISSN 0008-543X. PMID 18246537.
- ↑ Ouillette, Peter; et al. (2011-11-01). "The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia". Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 17 (21): 6778–6790. doi:10.1158/1078-0432.CCR-11-0785. ISSN 1078-0432. PMC 3207001. PMID 21890456.
- ↑ 41.0 41.1 Stevens-Kroef, Marian Jpl; et al. (2014-01-09). "Identification of prognostic relevant chromosomal abnormalities in chronic lymphocytic leukemia using microarray-based genomic profiling". Molecular Cytogenetics. 7 (1): 3. doi:10.1186/1755-8166-7-3. ISSN 1755-8166. PMC 3905918. PMID 24401281.
- ↑ Saddler, Chris; et al. (2008-02-01). "Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia". Blood. 111 (3): 1584–1593. doi:10.1182/blood-2007-09-112698. ISSN 0006-4971. PMID 17971485.
- ↑ Pei, Jianming; et al. (2014-03). "Copy neutral loss of heterozygosity in 20q in chronic lymphocytic leukemia/small lymphocytic lymphoma". Cancer Genetics. 207 (3): 98–102. doi:10.1016/j.cancergen.2014.02.005. ISSN 2210-7762. PMC 4010307. PMID 24704113. Check date values in:
|date=
(help) - ↑ Xu, Xinjie; et al. (2013-09). "The advantage of using SNP array in clinical testing for hematological malignancies--a comparative study of three genetic testing methods". Cancer Genetics. 206 (9–10): 317–326. doi:10.1016/j.cancergen.2013.09.001. ISSN 2210-7762. PMID 24269304. Check date values in:
|date=
(help)